Active, not recruitingPhase 2NCT03646461

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Studying Squamous cell carcinoma of the oropharynx

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Diego
Principal Investigator
Kathryn Gold, MD
University of California San Diego, Moores Cancer Center
Intervention
Ibrutinib 560mg PO daily (Imbruvica)(drug)
Enrollment
5 target
Eligibility
18 years · All sexes
Timeline
20182025

Study locations (1)

Collaborators

Pharmacyclics LLC.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03646461 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of the oropharynx

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of the oropharynx

← Back to all trials